COMBINING DISCRETE CHOICE EXPERIMENT AND CONTINGENT VALUATION TO ESTIMATE WILLINGNESS-TO-PAY FOR LYME DISEASE VACCINE ATTRIBUTES IN THE UNITED STATES
Author(s)
Matthew Wallace1, Joshua Coulter, MA2, Brett Hauber, PhD3, Marco Boeri, BSc, MSc, PhD4, Hannah L Gould1, Stephanie Duench5, Justin O'Hagan1, Divya Mohan6, Holly Yu, MSPH7;
1USA, 2Pfizer, Grand Rapids, MI, USA, 3Pfizer, New York, NY, USA, 4OPEN Health, Director of Preference Research at the Patient-Centered Outcomes, London, United Kingdom, 5Pfizer, Toronto, ON, Canada, 6OPEN Health, London, United Kingdom, 7Pfizer, Inc., Collegeville, PA, USA
1USA, 2Pfizer, Grand Rapids, MI, USA, 3Pfizer, New York, NY, USA, 4OPEN Health, Director of Preference Research at the Patient-Centered Outcomes, London, United Kingdom, 5Pfizer, Toronto, ON, Canada, 6OPEN Health, London, United Kingdom, 7Pfizer, Inc., Collegeville, PA, USA
OBJECTIVES: Lyme disease (LD) affects nearly half a million people annually in the United States (US), yet no vaccine is currently available. Understanding public preferences and willingness-to-pay (WTP) for an LD vaccine is critical for guiding development and pricing strategies. This study aimed to quantify WTP for an LD vaccine and identify which vaccine attributes most influence consumer choices among US.
METHODS: A web-based survey was administered to adults residing in high LD incidence or neighboring states. The DCE included three alternatives per task: two hypothetical vaccine profiles (defined by vaccine efficacy [45%, 65%, 80%, 90%], risk of mild systemic adverse events [AEs] [15%, 30%, 50%], risk of injection site reactions [30%, 50%, 90%], and risk of severe AEs requiring hospitalization [0.01%, 0.1%, 1%]) and no-vaccine. To avoid dominance or non-attendance, cost was excluded from the DCE. Following the DCE, respondents completed two double-bounded CV exercises, indicating whether they would accept both the best and worst vaccine profiles (fully administered in 4 doses) from the DCE at randomly assigned cost levels. The difference in WTP between profiles was combined with utility estimates from a random-parameters logit model to derive WTP for each change in attribute levels.
RESULTS: Data were collected from 2000 respondents (60% female, mean age 42, 75% living in suburban or rural areas). Mean WTP was $472.50 for the best vaccine profile and $396.60 for the worst, indicating that the majority of the WTP (over 75%) is attributable to desire for a vaccine, rather than improving vaccine attributes, as we only found $76 increased WTP when improving all attributes from worst to best levels.
CONCLUSIONS: Adults in high-incidence regions place substantial value on having an LD vaccine, regardless of attribute enhancements. These findings underscore the potential market demand and support value-based decision-making for future LD vaccine development.
METHODS: A web-based survey was administered to adults residing in high LD incidence or neighboring states. The DCE included three alternatives per task: two hypothetical vaccine profiles (defined by vaccine efficacy [45%, 65%, 80%, 90%], risk of mild systemic adverse events [AEs] [15%, 30%, 50%], risk of injection site reactions [30%, 50%, 90%], and risk of severe AEs requiring hospitalization [0.01%, 0.1%, 1%]) and no-vaccine. To avoid dominance or non-attendance, cost was excluded from the DCE. Following the DCE, respondents completed two double-bounded CV exercises, indicating whether they would accept both the best and worst vaccine profiles (fully administered in 4 doses) from the DCE at randomly assigned cost levels. The difference in WTP between profiles was combined with utility estimates from a random-parameters logit model to derive WTP for each change in attribute levels.
RESULTS: Data were collected from 2000 respondents (60% female, mean age 42, 75% living in suburban or rural areas). Mean WTP was $472.50 for the best vaccine profile and $396.60 for the worst, indicating that the majority of the WTP (over 75%) is attributable to desire for a vaccine, rather than improving vaccine attributes, as we only found $76 increased WTP when improving all attributes from worst to best levels.
CONCLUSIONS: Adults in high-incidence regions place substantial value on having an LD vaccine, regardless of attribute enhancements. These findings underscore the potential market demand and support value-based decision-making for future LD vaccine development.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
PCR112
Topic
Patient-Centered Research
Disease
STA: Vaccines